DADPS Biotin Azide
CAS No. 1260247-50-4
DADPS Biotin Azide( —— )
Catalog No. M33542 CAS No. 1260247-50-4
Biotin-PEG4-amino-t-Bu-DADPS-C6-azide is a PEGylated PROTAC linker suitable for PROTAC synthesis .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 223 | In Stock |
|
| 10MG | 353 | In Stock |
|
| 25MG | 582 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDADPS Biotin Azide
-
NoteResearch use only, not for human use.
-
Brief DescriptionBiotin-PEG4-amino-t-Bu-DADPS-C6-azide is a PEGylated PROTAC linker suitable for PROTAC synthesis .
-
DescriptionBiotin-PEG4-amino-t-Bu-DADPS-C6-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Biotin-PEG4-amino-t-Bu-DADPS-C6-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
-
In VitroPROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
In Vivo——
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPROTAC Linker
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1260247-50-4
-
Formula Weight886.18
-
Molecular FormulaC43H67N7O9SSi
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (112.84 mM; Ultrasonic )
-
SMILES[Si](OC(CNC(CCOCCOCCOCCOCCNC(CCCC[C@H]1[C@@]2([C@](CS1)(NC(=O)N2)[H])[H])=O)=O)(C)C)(OCCCCCCN=[N+]=[N-])(C3=CC=CC=C3)C4=CC=CC=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562?
molnova catalog
related products
-
JQ1-VHL-PROTAC
JQ1-VHL-PROTAC is a novel PROTAC synthesis.
-
TL13-112
TL13-112 is a novel Anaplastic Lymphoma Kinase (ALK)-PROTAC developed through conjugation of LDK378 and the cereblon ligand pomalidomide.
-
Boc-Val-Cit-PAB-PNP
Boc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.
Cart
sales@molnova.com